Loading…

In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis

Our objective was to determine the in vitro activity of minocycline against isolates of Burkholderia cepacia (BC), Stenotrophomonas maltophilia (SM), and Pseudomonas aeruginosa (PA) cultured from the respiratory tract of patients with cystic fibrosis (CF). Cultures of BC, SM, and PA were isolated in...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric pulmonology 2000-03, Vol.29 (3), p.210-212
Main Authors: Kurlandsky, Lawrence E., Fader, Robert C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3469-b3486c862ca00fd5a6619ce717c58c481e1c9ccb4cad71347db1070cb21309c03
container_end_page 212
container_issue 3
container_start_page 210
container_title Pediatric pulmonology
container_volume 29
creator Kurlandsky, Lawrence E.
Fader, Robert C.
description Our objective was to determine the in vitro activity of minocycline against isolates of Burkholderia cepacia (BC), Stenotrophomonas maltophilia (SM), and Pseudomonas aeruginosa (PA) cultured from the respiratory tract of patients with cystic fibrosis (CF). Cultures of BC, SM, and PA were isolated in a hospital bacteriology laboratory from the sputum or oropharyngeal cultures obtained from patients attending a Cystic Fibrosis Center, and were prospectively tested for in vitro sensitivity to minocycline by Kirby‐Bauer disk diffusion. From January 1994 to July 1995, 116 cultures from 61 patients had at least one of the three pathogens; 9/61 (15%) patients had an isolate of BC, and 7/9 (78%) had an initial isolate sensitive to minocycline, of which 3 were sensitive only to minocycline; 2 cultures were resistant to all antibiotics. Four of 7 patients with BC were treated with minocycline; 3 patients developed resistant isolates 3–13 months after therapy. Five of 61 patients (8%) had an isolate of SM: 4/5 (80%) of these isolates were sensitive to minocycline, of which 1 was sensitive only to minocycline. Fifty‐five of 61 patients (90%) had at least one PA isolate, with 112 morphotypes recovered from 90 cultures: 40/112 morphotypes (36%) were sensitive to minocycline, 65 (58%) were resistant, and 7 (6%) were intermediate in sensitivity. We conclude that the marked in vitro activity of minocycline against BC and SM isolated from patients with CF suggests that minocycline may have an adjunct role in the antimicrobial therapy of multidrug resistant, respiratory pathogens in CF. Pediatr Pulmonol. 2000; 29:210–212. © 2000 Wiley‐Liss, Inc.
doi_str_mv 10.1002/(SICI)1099-0496(200003)29:3<210::AID-PPUL9>3.0.CO;2-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70941850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70941850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3469-b3486c862ca00fd5a6619ce717c58c481e1c9ccb4cad71347db1070cb21309c03</originalsourceid><addsrcrecordid>eNqFkFtv0zAYhiMEYmXwF5AvENouUnzIyeUgTRkr1So6NFYuPzlfnc2QQ7FTRv79HFINJJDwhQ-fXj969QTBW0anjFL-6uhykS-OGZUypJFMjjj1SxxzORNvOKOz2cniNLy4uFrKd2JKp_nqNQ_5g2By_-NhMMnSOA6TLBEHwRPnvnqAlJI9Dg4Y9VMa8UmgFg35YTrbEoWd8beetCWpTdNij5VpNFHXyjSuI1a7rbGqa21Ptqq7aa9140hp23p4Gt10jtya7oZg7zqDpDSFbZ1xT4NHpaqcfrY_D4Ors_ef8w_hcjVf5CfLEEWUyLAQUZZglnBUlJabWCUJk6hTlmKcYZQxzVAiFhGqTcpElG4KRlOKBWeCSqTiMHg5cre2_b7TroPaONRVpRrd7hykVEYsi4fgvgD6fs7qErbW1Mr2wCgM7gEG9zCYhMEkjO6BS_CbD4F3D7_c-wGFfAUcuOc-3xfYFbXe_EEdZfvAi31AOVRVaVWDxv3O8SyTMvax9Ri7NZXu_yr3n27_qjYOPDgcwcZ1-uc9WNlvkKQijeHLxzmcr-NP6_npOVyKOwOevOI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70941850</pqid></control><display><type>article</type><title>In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis</title><source>Wiley</source><creator>Kurlandsky, Lawrence E. ; Fader, Robert C.</creator><creatorcontrib>Kurlandsky, Lawrence E. ; Fader, Robert C.</creatorcontrib><description>Our objective was to determine the in vitro activity of minocycline against isolates of Burkholderia cepacia (BC), Stenotrophomonas maltophilia (SM), and Pseudomonas aeruginosa (PA) cultured from the respiratory tract of patients with cystic fibrosis (CF). Cultures of BC, SM, and PA were isolated in a hospital bacteriology laboratory from the sputum or oropharyngeal cultures obtained from patients attending a Cystic Fibrosis Center, and were prospectively tested for in vitro sensitivity to minocycline by Kirby‐Bauer disk diffusion. From January 1994 to July 1995, 116 cultures from 61 patients had at least one of the three pathogens; 9/61 (15%) patients had an isolate of BC, and 7/9 (78%) had an initial isolate sensitive to minocycline, of which 3 were sensitive only to minocycline; 2 cultures were resistant to all antibiotics. Four of 7 patients with BC were treated with minocycline; 3 patients developed resistant isolates 3–13 months after therapy. Five of 61 patients (8%) had an isolate of SM: 4/5 (80%) of these isolates were sensitive to minocycline, of which 1 was sensitive only to minocycline. Fifty‐five of 61 patients (90%) had at least one PA isolate, with 112 morphotypes recovered from 90 cultures: 40/112 morphotypes (36%) were sensitive to minocycline, 65 (58%) were resistant, and 7 (6%) were intermediate in sensitivity. We conclude that the marked in vitro activity of minocycline against BC and SM isolated from patients with CF suggests that minocycline may have an adjunct role in the antimicrobial therapy of multidrug resistant, respiratory pathogens in CF. Pediatr Pulmonol. 2000; 29:210–212. © 2000 Wiley‐Liss, Inc.</description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/(SICI)1099-0496(200003)29:3&lt;210::AID-PPUL9&gt;3.0.CO;2-2</identifier><identifier>PMID: 10686042</identifier><identifier>CODEN: PEPUES</identifier><language>eng</language><publisher>New York: John Wiley &amp; Sons, Inc</publisher><subject>Adolescent ; Anti-Bacterial Agents - therapeutic use ; Biological and medical sciences ; Burkholderia cepacia ; Burkholderia cepacia - classification ; Burkholderia cepacia - drug effects ; Burkholderia Infections - drug therapy ; Child ; Child, Preschool ; cystic fibrosis ; Cystic Fibrosis - microbiology ; Drug Resistance, Multiple ; Female ; Gram-Negative Bacterial Infections - drug therapy ; Humans ; Male ; Medical sciences ; minocycline ; Minocycline - therapeutic use ; Oropharynx - microbiology ; Pharmacology. Drug treatments ; Prospective Studies ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - classification ; Pseudomonas aeruginosa - drug effects ; Pseudomonas Infections - drug therapy ; Respiratory system ; respiratory tract infection ; Respiratory Tract Infections - drug therapy ; Respiratory Tract Infections - microbiology ; Sputum - microbiology ; Stenotrophomonas maltophilia ; Stenotrophomonas maltophilia - classification ; Stenotrophomonas maltophilia - drug effects ; Stenotrophomonas maltophilia, Pseudomonas aeruginosa ; Tetracycline Resistance</subject><ispartof>Pediatric pulmonology, 2000-03, Vol.29 (3), p.210-212</ispartof><rights>Copyright © 2000 Wiley‐Liss, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3469-b3486c862ca00fd5a6619ce717c58c481e1c9ccb4cad71347db1070cb21309c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1288995$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10686042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kurlandsky, Lawrence E.</creatorcontrib><creatorcontrib>Fader, Robert C.</creatorcontrib><title>In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis</title><title>Pediatric pulmonology</title><addtitle>Pediatr. Pulmonol</addtitle><description>Our objective was to determine the in vitro activity of minocycline against isolates of Burkholderia cepacia (BC), Stenotrophomonas maltophilia (SM), and Pseudomonas aeruginosa (PA) cultured from the respiratory tract of patients with cystic fibrosis (CF). Cultures of BC, SM, and PA were isolated in a hospital bacteriology laboratory from the sputum or oropharyngeal cultures obtained from patients attending a Cystic Fibrosis Center, and were prospectively tested for in vitro sensitivity to minocycline by Kirby‐Bauer disk diffusion. From January 1994 to July 1995, 116 cultures from 61 patients had at least one of the three pathogens; 9/61 (15%) patients had an isolate of BC, and 7/9 (78%) had an initial isolate sensitive to minocycline, of which 3 were sensitive only to minocycline; 2 cultures were resistant to all antibiotics. Four of 7 patients with BC were treated with minocycline; 3 patients developed resistant isolates 3–13 months after therapy. Five of 61 patients (8%) had an isolate of SM: 4/5 (80%) of these isolates were sensitive to minocycline, of which 1 was sensitive only to minocycline. Fifty‐five of 61 patients (90%) had at least one PA isolate, with 112 morphotypes recovered from 90 cultures: 40/112 morphotypes (36%) were sensitive to minocycline, 65 (58%) were resistant, and 7 (6%) were intermediate in sensitivity. We conclude that the marked in vitro activity of minocycline against BC and SM isolated from patients with CF suggests that minocycline may have an adjunct role in the antimicrobial therapy of multidrug resistant, respiratory pathogens in CF. Pediatr Pulmonol. 2000; 29:210–212. © 2000 Wiley‐Liss, Inc.</description><subject>Adolescent</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Burkholderia cepacia</subject><subject>Burkholderia cepacia - classification</subject><subject>Burkholderia cepacia - drug effects</subject><subject>Burkholderia Infections - drug therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>cystic fibrosis</subject><subject>Cystic Fibrosis - microbiology</subject><subject>Drug Resistance, Multiple</subject><subject>Female</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>minocycline</subject><subject>Minocycline - therapeutic use</subject><subject>Oropharynx - microbiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - classification</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Respiratory system</subject><subject>respiratory tract infection</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Respiratory Tract Infections - microbiology</subject><subject>Sputum - microbiology</subject><subject>Stenotrophomonas maltophilia</subject><subject>Stenotrophomonas maltophilia - classification</subject><subject>Stenotrophomonas maltophilia - drug effects</subject><subject>Stenotrophomonas maltophilia, Pseudomonas aeruginosa</subject><subject>Tetracycline Resistance</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkFtv0zAYhiMEYmXwF5AvENouUnzIyeUgTRkr1So6NFYuPzlfnc2QQ7FTRv79HFINJJDwhQ-fXj969QTBW0anjFL-6uhykS-OGZUypJFMjjj1SxxzORNvOKOz2cniNLy4uFrKd2JKp_nqNQ_5g2By_-NhMMnSOA6TLBEHwRPnvnqAlJI9Dg4Y9VMa8UmgFg35YTrbEoWd8beetCWpTdNij5VpNFHXyjSuI1a7rbGqa21Ptqq7aa9140hp23p4Gt10jtya7oZg7zqDpDSFbZ1xT4NHpaqcfrY_D4Ors_ef8w_hcjVf5CfLEEWUyLAQUZZglnBUlJabWCUJk6hTlmKcYZQxzVAiFhGqTcpElG4KRlOKBWeCSqTiMHg5cre2_b7TroPaONRVpRrd7hykVEYsi4fgvgD6fs7qErbW1Mr2wCgM7gEG9zCYhMEkjO6BS_CbD4F3D7_c-wGFfAUcuOc-3xfYFbXe_EEdZfvAi31AOVRVaVWDxv3O8SyTMvax9Ri7NZXu_yr3n27_qjYOPDgcwcZ1-uc9WNlvkKQijeHLxzmcr-NP6_npOVyKOwOevOI</recordid><startdate>200003</startdate><enddate>200003</enddate><creator>Kurlandsky, Lawrence E.</creator><creator>Fader, Robert C.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200003</creationdate><title>In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis</title><author>Kurlandsky, Lawrence E. ; Fader, Robert C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3469-b3486c862ca00fd5a6619ce717c58c481e1c9ccb4cad71347db1070cb21309c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Burkholderia cepacia</topic><topic>Burkholderia cepacia - classification</topic><topic>Burkholderia cepacia - drug effects</topic><topic>Burkholderia Infections - drug therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>cystic fibrosis</topic><topic>Cystic Fibrosis - microbiology</topic><topic>Drug Resistance, Multiple</topic><topic>Female</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>minocycline</topic><topic>Minocycline - therapeutic use</topic><topic>Oropharynx - microbiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - classification</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Respiratory system</topic><topic>respiratory tract infection</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Respiratory Tract Infections - microbiology</topic><topic>Sputum - microbiology</topic><topic>Stenotrophomonas maltophilia</topic><topic>Stenotrophomonas maltophilia - classification</topic><topic>Stenotrophomonas maltophilia - drug effects</topic><topic>Stenotrophomonas maltophilia, Pseudomonas aeruginosa</topic><topic>Tetracycline Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kurlandsky, Lawrence E.</creatorcontrib><creatorcontrib>Fader, Robert C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kurlandsky, Lawrence E.</au><au>Fader, Robert C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr. Pulmonol</addtitle><date>2000-03</date><risdate>2000</risdate><volume>29</volume><issue>3</issue><spage>210</spage><epage>212</epage><pages>210-212</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><coden>PEPUES</coden><abstract>Our objective was to determine the in vitro activity of minocycline against isolates of Burkholderia cepacia (BC), Stenotrophomonas maltophilia (SM), and Pseudomonas aeruginosa (PA) cultured from the respiratory tract of patients with cystic fibrosis (CF). Cultures of BC, SM, and PA were isolated in a hospital bacteriology laboratory from the sputum or oropharyngeal cultures obtained from patients attending a Cystic Fibrosis Center, and were prospectively tested for in vitro sensitivity to minocycline by Kirby‐Bauer disk diffusion. From January 1994 to July 1995, 116 cultures from 61 patients had at least one of the three pathogens; 9/61 (15%) patients had an isolate of BC, and 7/9 (78%) had an initial isolate sensitive to minocycline, of which 3 were sensitive only to minocycline; 2 cultures were resistant to all antibiotics. Four of 7 patients with BC were treated with minocycline; 3 patients developed resistant isolates 3–13 months after therapy. Five of 61 patients (8%) had an isolate of SM: 4/5 (80%) of these isolates were sensitive to minocycline, of which 1 was sensitive only to minocycline. Fifty‐five of 61 patients (90%) had at least one PA isolate, with 112 morphotypes recovered from 90 cultures: 40/112 morphotypes (36%) were sensitive to minocycline, 65 (58%) were resistant, and 7 (6%) were intermediate in sensitivity. We conclude that the marked in vitro activity of minocycline against BC and SM isolated from patients with CF suggests that minocycline may have an adjunct role in the antimicrobial therapy of multidrug resistant, respiratory pathogens in CF. Pediatr Pulmonol. 2000; 29:210–212. © 2000 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>10686042</pmid><doi>10.1002/(SICI)1099-0496(200003)29:3&lt;210::AID-PPUL9&gt;3.0.CO;2-2</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 8755-6863
ispartof Pediatric pulmonology, 2000-03, Vol.29 (3), p.210-212
issn 8755-6863
1099-0496
language eng
recordid cdi_proquest_miscellaneous_70941850
source Wiley
subjects Adolescent
Anti-Bacterial Agents - therapeutic use
Biological and medical sciences
Burkholderia cepacia
Burkholderia cepacia - classification
Burkholderia cepacia - drug effects
Burkholderia Infections - drug therapy
Child
Child, Preschool
cystic fibrosis
Cystic Fibrosis - microbiology
Drug Resistance, Multiple
Female
Gram-Negative Bacterial Infections - drug therapy
Humans
Male
Medical sciences
minocycline
Minocycline - therapeutic use
Oropharynx - microbiology
Pharmacology. Drug treatments
Prospective Studies
Pseudomonas aeruginosa
Pseudomonas aeruginosa - classification
Pseudomonas aeruginosa - drug effects
Pseudomonas Infections - drug therapy
Respiratory system
respiratory tract infection
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Sputum - microbiology
Stenotrophomonas maltophilia
Stenotrophomonas maltophilia - classification
Stenotrophomonas maltophilia - drug effects
Stenotrophomonas maltophilia, Pseudomonas aeruginosa
Tetracycline Resistance
title In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A22%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activity%20of%20minocycline%20against%20respiratory%20pathogens%20from%20patients%20with%20cystic%20fibrosis&rft.jtitle=Pediatric%20pulmonology&rft.au=Kurlandsky,%20Lawrence%20E.&rft.date=2000-03&rft.volume=29&rft.issue=3&rft.spage=210&rft.epage=212&rft.pages=210-212&rft.issn=8755-6863&rft.eissn=1099-0496&rft.coden=PEPUES&rft_id=info:doi/10.1002/(SICI)1099-0496(200003)29:3%3C210::AID-PPUL9%3E3.0.CO;2-2&rft_dat=%3Cproquest_cross%3E70941850%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3469-b3486c862ca00fd5a6619ce717c58c481e1c9ccb4cad71347db1070cb21309c03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70941850&rft_id=info:pmid/10686042&rfr_iscdi=true